1.Sales and profit
See section β- OKYO Pharma Ltd lost $8.9M in fiscal 2026.
OKYO Pharma Ltd
OKYO Nasdaq Biological Products, (No Diagnostic Substances) Financials FY2020βFY2026
Download report
3-page PDF: the company, its results and charts with peers.
KIRAβs summary AI analyst
Hi! I read OKYO Pharma Ltdβs latest annual report (fiscal 2026). Here is what stands out:
2 to watch
2.Cash and shareholders
See section β- Free cash flow was β$5.9M in fiscal 2026, β of revenue.
- No open-market insider trades in the last 12 months.
OKYO Pharma Ltd in 30 seconds
Good So-so Weak
Weak
Does it make a profit?
β$8.9M
No. It lost money last year.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Key numbers, fiscal 2026
Market cap
Last close times the latest diluted share count, so it is approximate.
β
P/E
Last close divided by diluted earnings per share over the last four quarters.
β
Sales and profit
Is it selling more, and how much does it keep?
Results dates
In plain words: Every quarter, companies publish how much they sold and earned. These are the days OKYO Pharma Ltd did it, and the next one. Share prices often move a lot on those days.
Next results
July 19, 2027
Monday Β· in 266 days
- Time
- Before the market opens
- Covers
- Period ended Mar 31, 2027
- Source
- Stoqly estimate
Estimated from the same quarter last year. It will be replaced by the announced date once there is one.
See who else reports that week β| Date | Results for | Time | Source |
|---|---|---|---|
| Jul 20, 2026 | Period ended Mar 31, 2026 | Before the market opens | 20-F β |
| Jul 18, 2025 | Period ended Mar 31, 2025 | After the market closes | 20-F β |
| Aug 13, 2024 | Period ended Mar 31, 2024 | After the market closes | 20-F β |
| Aug 15, 2023 | Period ended Mar 31, 2023 | Time not announced | 20-F β |
| Aug 15, 2022 | Period ended Mar 31, 2022 | During market hours | 20-F β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
Revenue and margins
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
FY20
Revenue β
FY21
Revenue β
FY22
Revenue β
FY23
Revenue β
FY24
Revenue β
FY25
Revenue β
FY26
Revenue β
Margins, % of revenue
FY20
Gross β
Operating β
Net β
FCF β
FY21
Gross β
Operating β
Net β
FCF β
FY22
Gross β
Operating β
Net β
FCF β
FY23
Gross β
Operating β
Net β
FCF β
FY24
Gross β
Operating β
Net β
FCF β
FY25
Gross β
Operating β
Net β
FCF β
FY26
Gross β
Operating β
Net β
FCF β
Gross
Operating
Net
FCF
Net income and earnings per share
KIRA Β· OKYO Pharma Ltd lost $8.9M in fiscal 2026.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
FY20
Net income β$1.5M
FY21
Net income β$3.4M
FY22
Net income β$5.4M
FY23
Net income β$13.3M
FY24
Net income β$16.8M
FY25
Net income β$4.7M
FY26
Net income β$8.9M
Diluted EPS
FY20
Diluted EPS β
FY21
Diluted EPS β$0.32
FY22
Diluted EPS β$0.36
FY23
Diluted EPS β$0.61
FY24
Diluted EPS β$0.57
FY25
Diluted EPS β$0.12
FY26
Diluted EPS β$0.24
Cash and shareholders
How much cash comes in, and where does it go?
Cash flow
KIRA Β· Free cash flow was β$5.9M in fiscal 2026, β of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
FY20
Free cash flow β
FY21
Free cash flow β$1.6M
FY22
Free cash flow β$5.5M
FY23
Free cash flow β$7.7M
FY24
Free cash flow β
FY25
Free cash flow β$1.8M
FY26
Free cash flow β$5.9M
Cash from operations vs capital spending
FY20
Cash from operations β$1.2M
Capital spending β
FY21
Cash from operations β$1.6M
Capital spending $0.0M
FY22
Cash from operations β$5.5M
Capital spending $0.0M
FY23
Cash from operations β$7.7M
Capital spending $0.0M
FY24
Cash from operations β$9.5M
Capital spending β
FY25
Cash from operations β$1.8M
Capital spending $0.0M
FY26
Cash from operations β$5.9M
Capital spending $0.0M
Cash from operations
Capital spending
Dividends, buybacks and share count
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
FY20
Dividends β
Buybacks β
FY21
Dividends β
Buybacks β
FY22
Dividends β
Buybacks β
FY23
Dividends β
Buybacks β
FY24
Dividends β
Buybacks β
FY25
Dividends β
Buybacks β
FY26
Dividends β
Buybacks β
Dividends
Buybacks
Diluted shares outstanding (annual)
FY20
Diluted shares 0.60B
FY21
Diluted shares 0.67B
FY22
Diluted shares 0.98B
FY23
Diluted shares β
FY24
Diluted shares β
FY25
Diluted shares β
FY26
Diluted shares β
Insider trades
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Financial health
Can it carry its debts, and how well does it use its money?
Balance sheet
Cash, debt and the ratios that show how comfortably OKYO Pharma Ltd can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
FY20
Cash $0.2M
Debt β
FY21
Cash $6.9M
Debt β
FY22
Cash $2.7M
Debt β
FY23
Cash $4.0M
Debt β
FY24
Cash $0.8M
Debt β
FY25
Cash $1.6M
Debt $2.7M
FY26
Cash $14.6M
Debt β
Cash
Debt
| Fiscal year end | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash and short-term investments | $2.7M | $4.0M | $0.8M | $1.6M | $14.6M |
| Debt incl. finance leases | β | β | β | $2.7M | β |
| Current ratio | 3.2x | 0.7x | 0.2x | 0.4x | 2.4x |
| Quick ratio | 3.2x | 0.7x | 0.2x | 0.4x | 2.4x |
| Total assets | $4.3M | $5.2M | $1.5M | $3.7M | $21.0M |
| Total liabilities | $1.4M | $7.3M | $7.4M | $9.2M | $8.6M |
| Shareholders' equity | $2.9M | β$2.1M | β$5.9M | β$5.5M | $12.3M |
| Net debt (β = net cash) | β | β | β | $1.1M | β |
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
FY20
Return on capital β
Return on equity β
Return on assets β
FY21
Return on capital β
Return on equity β129.5%
Return on assets β47.3%
FY22
Return on capital β
Return on equity β131.4%
Return on assets β95.3%
FY23
Return on capital β
Return on equity β2,968.4%
Return on assets β279.3%
FY24
Return on capital β
Return on equity β
Return on assets β498.9%
FY25
Return on capital β
Return on equity β
Return on assets β180.4%
FY26
Return on capital β
Return on equity β263.8%
Return on assets β72.6%
Return on capital
Return on equity
Return on assets
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β |
| F-score | β / 3 | β / 4 | β / 6 | β / 5 | β / 5 | β / 5 | β / 5 |
| Accruals ratio | β | β24.7% | 0.7% | β117.3% | β217.5% | β111.0% | β24.4% |
| Altman Z'' | β | β | β | β | β | β | β |
All figures
Every number, year by year.
7 years of figures
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Research and development | $0.5M | $0.3M | $1.6M | $6.3M | $8.2M | $2.3M | $1.8M |
| Interest expense | $0.0M | $0.0M | β | $0.1M | $1.1M | $0.9M | $0.5M |
| Pretax income | β$1.6M | β$3.4M | β$6.2M | β$13.3M | β$16.8M | β$8.0M | β$8.9M |
| Income tax | $0.1M | $0.0M | $0.8M | $0.0M | β$0.0M | $3.3M | β$0.0M |
| Net income | β$1.5M | β$3.4M | β$5.4M | β$13.3M | β$16.8M | β$4.7M | β$8.9M |
| Diluted EPS | β | β$0.32 | β$0.36 | β$0.61 | β$0.57 | β$0.12 | β$0.24 |
| Diluted shares | 0.60B | 0.67B | 0.98B | β | β | β | β |
| Cash flow | |||||||
| Cash from operations | β$1.2M | β$1.6M | β$5.5M | β$7.7M | β$9.5M | β$1.8M | β$5.9M |
| Capital expenditure | β | $0.0M | $0.0M | $0.0M | β | $0.0M | $0.0M |
| Free cash flow | β | β$1.6M | β$5.5M | β$7.7M | β | β$1.8M | β$5.9M |
| Depreciation and amortization | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Stock-based compensation | $0.0M | $0.6M | $1.7M | $1.3M | $1.1M | $0.7M | $1.6M |
| Balance sheet | |||||||
| Cash and short-term investments | $0.2M | $6.9M | $2.7M | $4.0M | $0.8M | $1.6M | $14.6M |
| Total debt | β | β | β | β | β | $2.7M | β |
| Current assets | β | $7.0M | $4.3M | $5.2M | $1.5M | $3.7M | $21.0M |
| Current liabilities | β | $1.7M | $1.4M | $7.3M | $7.4M | $9.2M | $8.6M |
| Property and equipment, net | β | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Total assets | β | $7.1M | $4.3M | $5.2M | $1.5M | $3.7M | $21.0M |
| Total liabilities | β | $1.8M | $1.4M | $7.3M | $7.4M | $9.2M | $8.6M |
| Shareholders' equity | β$0.1M | $5.3M | $2.9M | β$2.1M | β$5.9M | β$5.5M | $12.3M |
| Returns | |||||||
| Return on equity | β | β129.5% | β131.4% | β2,968.4% | β | β | β263.8% |
| Return on assets | β | β47.3% | β95.3% | β279.3% | β498.9% | β180.4% | β72.6% |
| Return on tangible equity | β | β63.0% | β184.3% | β | β | β | β72.6% |
| Growth | |||||||
| Share count change | β | 13.0% | 45.5% | β | β | β | β |
| Financial health | |||||||
| Current ratio | β | 4.1x | 3.2x | 0.7x | 0.2x | 0.4x | 2.4x |
| Quick ratio | β | 4.1x | 3.2x | 0.7x | 0.2x | 0.4x | 2.4x |
| Quality scores | |||||||
| Accruals ratio | β | β24.7% | 0.7% | β117.3% | β217.5% | β111.0% | β24.4% |
Source: SEC EDGAR XBRL filings (CIK 0001849296). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. The ADS ratio could not be read from the filing, so market cap and valuation are not shown. For information only β not investment advice. Check the original filings before relying on any figure.